about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Insights into CYP2B6-mediated drug-drug interactionsPharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settingsWorldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.Pharmacotherapy of pediatric HIV infectionIndividualization of antiretroviral therapy.Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceMechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamicsImpact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Pharmacogenetics of antiretroviral therapy.Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa.Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells.CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil.Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats.Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia.Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug-Efavirenz.Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods.Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6.Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q24628212-75CF45FA-C786-4AB3-B466-2C15ABA67332Q27012807-C4A9A778-0FCE-40CA-8484-8C3CE4A4927DQ28078857-B435EDAD-FAFD-43F6-8E0A-56B5885BFD9BQ33797850-92BE7749-5BCE-4819-B168-FFAECA580360Q34938889-2EF49916-6BE8-4734-9618-23190D052E86Q35692270-D5505887-A817-4DE4-84BF-C35BAD142EC8Q36031230-349DBA20-35D9-4832-9124-0FC0113DD314Q36079108-8643C286-9BB2-4039-93FA-9FEA9A08830AQ36230046-5DA716B2-4E87-4D98-AEB7-47FB6209F25FQ36263781-88B30557-E045-4866-9BA2-FDBFAB3C7E8CQ36301325-75529D0A-E6EF-4B3F-9313-DB7EBB01C0B1Q36441423-7DE4E10F-B993-476D-871D-CD91C1E50A2CQ36571936-04698A91-4282-4FC4-A73C-0A00275E336FQ36657589-4F886524-C041-4725-BA40-D39B917F2094Q36693543-60E10F64-8C9B-488B-A049-2A57651B3D3FQ36887174-88E2921E-C980-49FF-99A6-A0BEABAFE992Q37866289-ABCF1F69-D0EF-4D82-AFDB-83E23C1666E2Q37866298-651CFFC3-090B-4CC2-9CFC-3FED638838D0Q38175870-D569CF96-462F-46E0-8133-077C91716410Q38221179-26089B28-5A6B-47E0-BA6D-FB70137A5D87Q38371653-235AF9FD-752A-423B-BBB9-B0FE5C19BDEFQ38911295-E1AD9994-9758-4BD1-B452-AA20311D2277Q40206331-BAC9E943-407F-48C5-B421-B18BD836E668Q40708931-DA6EB6F3-D0EF-4504-9DFD-FA8060E8B6ABQ41333285-A236DDC1-62DD-497F-9502-6D925E475251Q42011164-6408A165-1B6A-403A-8E64-357B3EDD562DQ42199787-F517BF49-9CB3-4683-AE6C-D5CF7A1065F4Q42260849-2EA125A1-06FA-4846-B14E-6099356C7916Q45132328-496D6221-07C0-44EA-98EE-3112B924E416Q49215469-320F6A4D-9143-406C-BCDD-05BA9A6E524DQ52599217-C86523DE-70C6-43C8-B0E3-5E9BAEBFECF4Q54260617-904118EE-30E8-4116-8F98-924E82B97E46Q58073610-AC1C4E61-D1E1-4D90-AD37-CEDA1FEEE67F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efavirenz in the therapy of HIV infection.
@ast
Efavirenz in the therapy of HIV infection.
@en
type
label
Efavirenz in the therapy of HIV infection.
@ast
Efavirenz in the therapy of HIV infection.
@en
prefLabel
Efavirenz in the therapy of HIV infection.
@ast
Efavirenz in the therapy of HIV infection.
@en
P2860
P1476
Efavirenz in the therapy of HIV infection
@en
P2093
John N van den Anker
P2860
P304
P356
10.1517/17425250903483207
P407
P577
2010-01-01T00:00:00Z